Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.

The post Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program appeared first on MedCity News.

The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.

The post Alcon ups its glaucoma game again with $770M Aerie Pharma acquisition appeared first on MedCity News.

The company’s technology for screening diabetic retinopathy was granted “Breakthrough Device” designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.

The post IDx raises $33M Series A after its AI-powered screening tool received an FDA nod appeared first on MedCity News.

The post Glaukos gets the OK from Japan for its iStent device designed to treat glaucoma appeared first on MedCity News.

The post Eye care technology company Vizzario brings in $2M, but to go toward what exactly? appeared first on MedCity News.

The post InnFocus closes Series C financing with $33.9M for glaucoma device appeared first on MedCity News.